Roberto Alvarenga, general manager Latin America at Biotronik, the leading company globally for cardiovascular and endovascular medical technologies, documents how he has been leveraging on his long standing experience among prestigious pharmaceutical companies in order to implement pioneering processes in Brazil’s medtech field and ultimately increase Brazilian patients’ access to innovation.
You undoubtedly stand as one of the most experienced executives in the country’s pharmaceutical sector, having honed a long-standing expertise at the head of the Brazilian affiliates of Ferring, Shire, and Merck Serono. What motivated you to move to the medtech side?
"I believe that Brazilians should take pride on our public health system, especially given that it covers over 208 million inhabitants."
